Related references
Note: Only part of the references are listed.VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives
Chao Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
HDAC8 suppresses the epithelial phenotype and promotes EMT in chemotherapy-treated basal-like breast cancer
Garyfallia Pantelaiou-Prokaki et al.
CLINICAL EPIGENETICS (2022)
Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic
Zhenyi Hu et al.
CHEMBIOCHEM (2022)
Optimization of Class I Histone Deacetylase PROTACs Reveals thatHDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells
Joshua P. Smalley et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Attenuation of NLRP3 Inflammasome Activation by Indirubin-Derived PROTAC Targeting HDAC6
Zhuoxian Cao et al.
ACS CHEMICAL BIOLOGY (2021)
HDAC8 promotes daunorubicin resistance of human acute myeloid leukemia cells via regulation of IL-6 and IL-8
Jieying Wu et al.
BIOLOGICAL CHEMISTRY (2021)
Developments of CRBN-based PROTACs as potential therapeutic agents
Chao Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
The rise and rise of protein degradation: Opportunities and challenges ahead
Scott J. Hughes et al.
DRUG DISCOVERY TODAY (2021)
Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma
Yalin Tu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Advancing targeted protein degradation for cancer therapy
Brandon Dale et al.
NATURE REVIEWS CANCER (2021)
miR-483-3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8 oncogene
Mohammad-Nazir Menbari et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia
Jun Long et al.
BLOOD (2020)
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
George M. Burslem et al.
CELL (2020)
Harnessing the Power of Proteolysis for Targeted Protein Inactivation
Rati Verma et al.
MOLECULAR CELL (2020)
HDAC8 cooperates with SMAD3/4 complex to suppress SIRT7 and promote cell survival and migration
Xiaolong Tang et al.
NUCLEIC ACIDS RESEARCH (2020)
AMPK-dependent phosphorylation of HDAC8 triggers PGM1 expression to promote lung cancer cell survival under glucose starvation
Yanping Li et al.
CANCER LETTERS (2020)
Development of Selective Histone Deacetylase 6 (HDAC6) Degraders Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase
Ka Yang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Proteolysis targeting chimeras (PROTACs) for epigenetics research
Anja Vogelmann et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2020)
Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC)
Fangyuan Cao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders
Ka Yang et al.
CELL CHEMICAL BIOLOGY (2020)
Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity
Hao Wu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Developing potent PROTACs tools for selective degradation of HDAC6 protein
Zixuan An et al.
PROTEIN & CELL (2019)
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
Bing Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Diverse classes of HDAC8 inhibitors: in search of molecular fingerprints that regulate activity
Sk Abdul Amin et al.
FUTURE MEDICINAL CHEMISTRY (2018)
Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants
Martin Marek et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity
Tino Heimburg et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Alterations in histone deacetylase 8 lead to cell migration and poor prognosis in breast cancer
Chang-Lin Hsieh et al.
LIFE SCIENCES (2016)
Development of a Potent and Selective HDAC8 Inhibitor
Oscar J. Ingham et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Histone deacetylases: structural determinants of inhibitor selectivity
Carmina Micelli et al.
DRUG DISCOVERY TODAY (2015)
The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma
Shiyuan Song et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST)
Gonzalo Lopez et al.
PLOS ONE (2015)
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Edward Seto et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
HDAC8 and STAT3 repress BMF gene activity in colon cancer cells
Y. Kang et al.
CELL DEATH & DISEASE (2014)
SOX4 is a direct target gene of FRA-2 and induces expression of HDAC8 in adult T-cell leukemia/lymphoma
Tomonori Higuchi et al.
BLOOD (2013)
The novel HDAC inhibitor NDACI054 sensitizes human cancer cells to radiotherapy
Stephanie Hehlgans et al.
RADIOTHERAPY AND ONCOLOGY (2013)
MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy
Steffan T. Nawrocki et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer
Soon Young Park et al.
ONCOLOGY REPORTS (2011)
Chemical phylogenetics of histone deacetylases
James E. Bradner et al.
NATURE CHEMICAL BIOLOGY (2010)
Azetidinones as Zinc-Binding Groups to Design Selective HDAC8 Inhibitors
Paola Galletti et al.
CHEMMEDCHEM (2009)
Epigenetic control of skull morphogenesis by histone deacetylase 8
Michael Haberland et al.
GENES & DEVELOPMENT (2009)
The many roles of histone deacetylases in development and physiology: implications for disease and therapy
Michael Haberland et al.
NATURE REVIEWS GENETICS (2009)
A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas
S. Balasubramanian et al.
LEUKEMIA (2008)
Histone deacetylation in epigenetics: An attractive target for anticancer therapy
A Mai et al.
MEDICINAL RESEARCH REVIEWS (2005)
Epigenetics - An epicenter of gene regulation: Histones and histone-modifying enzymes
M Biel et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2005)
Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response
GD Kao et al.
JOURNAL OF CELL BIOLOGY (2003)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
